Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1299695 | 0.83 | MEP1B (0.47) | TSHRMAPK1MCL1KMT2ALMNA | |
| SCHEMBL2122256 | 0.83 | TSHR (0.50) | TSHRMAPK1RXFP1MCL1KMT2A | |
| SCHEMBL896792 | 0.83 | TSHR (0.50) | TSHRMAPK1RXFP1MCL1KMT2A | |
| SCHEMBL4618409 | 0.81 | TSHR (0.49) | TSHRMAPK1RXFP1MCL1KMT2A | |
| SCHEMBL4572915 | 0.81 | L3MBTL1 (0.59) | TSHRMAPK1RXFP1MCL1KMT2A | |
| SCHEMBL1727450 | 0.79 | PDIA6 (0.51) | TSHRMAPK1RXFP1MCL1KMT2A | |
| SCHEMBL181280 | 0.79 | TSHR (0.47) | TSHRMAPK1RXFP1MCL1KMT2A | |
| SCHEMBL16339268 | 0.79 | TSHR (0.47) | TSHRMAPK1RXFP1MCL1KMT2A | |
| SCHEMBL7803001 | 0.79 | TSHR (0.47) | TSHRMAPK1RXFP1MCL1KMT2A | |
| SCHEMBL29764212 | 0.79 | TSHR (0.47) | TSHRMAPK1RXFP1MCL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1541563-A1 | CCR4 ANTAGONIST AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | CCR4, CCR1, CCR9 | TSHR 1265/4885MAPK1 615/4885RXFP1 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.